Sidney Gorton, MD
Internal Medicine · Belzoni, MSNPI 1972572683
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,852 of the $7,055 with a category attached, or 68.8%. It is spread thinly across 24 manufacturers, the largest accounting for just 19.1%. Reporting peaked in 2020 at $2,124 and has fallen 72.3% since, to $588 in 2025. Among internal medicine clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $30.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Novo Nordisk$1K
- Bayer$1K
- AstraZeneca$976
- Johnson & Johnson$432
- Boehringer Ingelheim$336
- plus $1K from 18 others
Across 87 payments — averaging $6485.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$457K
- Novo Nordisk AS$107K
What the payments were for
- Consulting fees$1,15916%
- Travel & lodging$1,03115%
- Food & beverage$4,85269%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 9 | $1,345 |
| Novo Nordisk | 63 | $1,281 |
| Bayer | 7 | $1,247 |
| AstraZeneca | 25 | $976 |
| Johnson & Johnson | 29 | $432 |
| Boehringer Ingelheim | 22 | $336 |
| Lilly USA, LLC | 13 | $243 |
| Lundbeck LLC | 10 | $208 |
| Merck | 9 | $196 |
| GSK | 10 | $155 |
| Pfizer | 8 | $108 |
| Sanofi-aventis U.S. LLC | 6 | $84 |
| Amarin Pharma, Inc. | 5 | $73 |
| Abbott | 4 | $71 |
| Amgen | 3 | $52 |
| AbbVie | 3 | $47 |
| Mylan Specialty L.p. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 1 | $32 |
| Verona Pharma, Inc. | 1 | $30 |
| Insulet Corporation | 1 | $28 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LEQVIO$1,255
- Non-Covered$1,159
- FARXIGA$327
- Ozempic$250
- RYBELSUS$227
- BREZTRI AEROSPHERE$124
- BREZTRI$124
- AIRSUPRA$107
How this compares
$7,055 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 407 | $234,342 |
| FarxigaDapagliflozin Propanediol | 395 | $197,299 |
| Tresiba Flextouch U-200Insulin Degludec | 167 | $161,157 |
| JardianceEmpagliflozin | 238 | $157,206 |
| OzempicSemaglutide | 137 | $145,004 |
| LinzessLinaclotide | 206 | $111,891 |
| EliquisApixaban | 231 | $111,748 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 139 | $100,095 |
| EntrestoSacubitril/Valsartan | 122 | $87,715 |
| RybelsusSemaglutide | 82 | $84,184 |
| TradjentaLinagliptin | 168 | $75,907 |
| JanumetSitagliptin Phos/Metformin Hcl | 82 | $48,066 |
| XareltoRivaroxaban | 90 | $46,639 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $39,052 |
| Tresiba Flextouch U-100Insulin Degludec | 112 | $32,264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Janumet Xr | $196 | $301,509523 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Jentadueto | $336 | $252,444439 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $976 | $241,818507 claims |
| Novo NordiskOzempic, Rybelsus | $1,281 | $229,189219 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $155 | $130,032208 claims |
| AbbVieLinzess, Lumigan | $47 | $118,773232 claims |
| PfizerEliquis | $108 | $111,748231 claims |
| NovartisEntresto | $1,345 | $87,715122 claims |
| Johnson & JohnsonXarelto | $432 | $46,63990 claims |
| Lilly USA, LLCMounjaro, Trulicity | $243 | $31,97433 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $32 | $23,89526 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $13,21832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Belzoni
- Kelly WilkinsonJackson$79K
- Shanna PettieJackson$53K
- Gabriel HernandezJackson$41K
- Indira VeerisettyRidgeland$25K
- James BridgesMadison$23K
- Brendan RossJackson$19K
- Hassan CheemaJackson$16K
- Jeffrey DennisOxford$15K
- Charles HillOxford$15K
- Paul VolanskyCorinth$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.